Media Release
Second Bisantrene Patent allowed in US
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled,
- Posted by: Race Oncology
FeaturedMedia Release
Race Oncology releases Investor Presentation
Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy’s address at the BIO CEO Conference in New York City. View the presentation here: Race Oncology Investor
- Posted by: Race Oncology
FeaturedMedia Release
Bisantrene Patent in US granted “Notice of Allowance”
A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent
- Posted by: Race Oncology
Media Release
Race to present at J.P. Morgan Biotech Conference in US
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief
- Posted by: Race Oncology
Media Release
Melbourne research institute in global cancer collaboration led by Swiss biotech firm
Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the
- Posted by: Race Oncology
Video
Race interview at Biotech and Money Conference
In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.
- Posted by: Race Oncology
Video
Edison TV research interview
What is Bisantrene and where did it come from? Click here to watch CEO Peter Molloy’s interview on Edison TV.
- Posted by: Race Oncology